We are live on
!
Find out more
SCM
Sio Capital Management Portfolio holdings
AUM
$604M
1-Year Est. Return
96.57%
This Fund
S&P 500
This Quarter
Est. Return
-7.37%
1 Year Est. Return
+96.57%
3 Year Est. Return
+564.25%
5 Year Est. Return
+486.18%
10 Year Est. Return
+2,856.71%
AUM
$310M
AUM Growth
-$104M
(-25%)
Cap. Flow
-$16.3M
Cap. Flow
% of AUM
-5.26%
Top 10 Holdings %
Top 10 Hldgs %
43.58%
Holding
95
New
25
Increased
9
Reduced
24
Closed
33
Avg Time Held Equity + Options
2.1
quarters
Top 10 Avg Time Held Equity + Options
1.3
quarters
Top 20 Avg Time Held Equity + Options
1.1
quarters
Avg Time Held Equity only
2.4
quarters
Top 10 Avg Time Held Equity only
1.3
quarters
Top 20 Avg Time Held Equity only
1.3
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Johnson & Johnson
JNJ
|
+$18.9M |
| 2 |
AGN
Allergan plc
AGN
|
+$16.4M |
| 3 |
Pfizer
PFE
|
+$11M |
| 4 |
McKesson
MCK
|
+$8.96M |
| 5 |
Cencora
COR
|
+$8.86M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
GSK
GSK
|
+$15.2M |
| 2 |
LJPC
La Jolla Pharmaceutical Company
LJPC
|
+$12.1M |
| 3 |
Medpace
MEDP
|
+$10.2M |
| 4 |
Novartis
NVS
|
+$8.3M |
| 5 |
Humana
HUM
|
+$7.51M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 89.52% |
| 2 | Miscellaneous | 10.48% |
| 3 | Technology | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
GWPH
1
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
| $20.7M | 6.66% |
179,714
+55,550
| +45% | +$8.43M |
2018 Q4
3 quarters
|
|
|
2
Johnson & Johnson
JNJ
$599B
| $18.6M | 5.99% |
+143,707
| New | +$18.9M |
2019 Q3
0 quarters
|
|
|
AGN
3
DELISTED
Allergan plc
AGN
| $16.9M | 5.45% |
+100,629
| New | +$16.4M |
2019 Q3
0 quarters
|
|
4
HCA Healthcare
HCA
$99.8B
| $16.2M | 5.22% |
134,599
-22,585
| -14% | -$2.92M |
2018 Q1
6 quarters
|
|
|
WCG
5
DELISTED
Wellcare Health Plans, Inc.
WCG
| $13.1M | 4.21% |
50,435
-12,060
| -19% | -$3.33M |
2019 Q1
2 quarters
|
|
6
Coherus Oncology
CHRS
$165M
| $12.3M | 3.95% |
604,785
+420,419
| +228% | +$8.4M |
2019 Q2
1 quarter
|
|
|
7
Pfizer
PFE
$162B
| $10.3M | 3.32% |
+301,918
| New | +$11M |
2019 Q3
0 quarters
|
|
8
Alnylam Pharmaceuticals
ALNY
$29.9B
| $9.86M | 3.18% |
122,653
-28,900
| -19% | -$2.29M |
2018 Q2
5 quarters
|
|
9
Medtronic
MDT
$119B
| $8.77M | 2.82% |
80,702
-15,762
| -16% | -$1.64M |
2018 Q3
4 quarters
|
|
|
10
McKesson
MCK
$112B
| $8.64M | 2.78% |
+63,190
| New | +$8.96M |
2019 Q3
0 quarters
|
|
|
11
Cencora
COR
$63B
| $8.49M | 2.73% |
+103,103
| New | +$8.86M |
2019 Q3
0 quarters
|
|
12
DELISTED
BioTelemetry, Inc.
BEAT
| $7.78M | 2.51% |
191,040
+37,085
| +24% | +$1.6M |
2019 Q2
1 quarter
|
|
|
MRTX
13
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $7.52M | 2.42% |
96,525
-38,775
| -29% | -$3.64M |
2019 Q1
2 quarters
|
|
14
Avantor
AVTR
$10.5B
| $6.99M | 2.25% |
475,609
+254,022
| +115% | +$4.3M |
2019 Q2
1 quarter
|
|
15
United Therapeutics
UTHR
$23.3B
| $6.99M | 2.25% |
87,664
+4,772
| +6% | +$384K |
2018 Q4
3 quarters
|
|
16
Regeneron Pharmaceuticals
REGN
$77.5B
| $6.87M | 2.21% |
+24,776
| New | +$7.33M |
2019 Q3
0 quarters
|
|
17
Elevance Health
ELV
$92.2B
| $6.55M | 2.11% |
27,285
-2,054
| -7% | -$563K |
2019 Q2
1 quarter
|
|
18
PUT
CEL-SCI Corp
CVM
$30.8M
| $6.22M | 2% |
+23,187
| New | +$5.43M |
2019 Q3
0 quarters
|
|
19
InMode
INMD
$823M
| $5.79M | 1.87% |
+538,766
| New | +$6.14M |
2019 Q3
0 quarters
|
|
|
DRNA
20
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
| $5.31M | 1.71% |
369,494
-156,565
| -30% | -$2.24M |
2018 Q4
3 quarters
|
|
21
Viking Therapeutics
VKTX
$3.39B
| $5.19M | 1.67% |
754,759
| – | – |
2017 Q4
7 quarters
|
|
|
SPPI
22
DELISTED
Spectrum Pharmaceuticals Inc
SPPI
| $5.13M | 1.65% |
619,019
+15,000
| +2% | +$121K |
2019 Q1
2 quarters
|
|
|
ALXN
23
DELISTED
Alexion Pharmaceuticals
ALXN
| $5.02M | 1.62% |
51,281
-20,240
| -28% | -$2.28M |
2018 Q3
4 quarters
|
|
24
Halozyme
HALO
$12.4B
| $4.97M | 1.6% |
+320,373
| New | +$5.28M |
2019 Q3
0 quarters
|
|
25
CALL
Axsome Therapeutics
AXSM
$8.19B
| $4.84M | 1.56% |
+239,000
| New | +$6.14M |
2019 Q3
0 quarters
|
|
Similar funds
EFL
V
MAM
RCM
AMG
VV
VCP
EHI
Sio Capital Management's Q3 2019 Portfolio in Review
As of Q3 2019, Sio Capital Management held 95 positions worth $310M, down 25% from $415M the previous quarter. Its ten largest holdings account for 44% of the portfolio.
Sio Capital Management withdrew a net $16.3M in Q3 2019, closing 33 positions and reducing 24 holdings. Its most notable exit was GSK, an estimated $15.2M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 90% of assets, up from 77% a quarter earlier, followed by Miscellaneous and Technology.
Against the trend, Sio Capital Management opened a new position in Johnson & Johnson worth $18.6M.
- Sio Capital Management's largest Q3 2019 buy was Johnson & Johnson: 143,707 shares worth $18.6M.
- Sio Capital Management added most to GW Pharmaceuticals Plc American Depositary Shares in Q3 2019, an estimated $8.43M increase.
- Sio Capital Management's biggest Q3 2019 reduction was Medpace, cutting an estimated $10.2M.
- Sio Capital Management fully exited GSK in Q3 2019, selling an estimated $15.2M.
- Sio Capital Management's ten largest holdings make up 44% of its $310M portfolio in Q3 2019.
- Sio Capital Management opened 25 new positions and closed 33 in Q3 2019.
- Sio Capital Management's portfolio value fell 25% quarter-over-quarter to $310M.
Based on Sio Capital Management's 13F filing for Q3 2019, filed 14 Nov 2019.